Cheng Yi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cheng Yi has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
Xi Yang
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
5 shared publications- Ying Huang
West China School of Basic Medical Science and Forensic Medicine, Sichuan University, Chengdu, People’s Republic of China
5 shared publications Dan Cao
Sichuan University
4 shared publications- Changyang Gong
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
3 shared publications Fen Zhao
Department of Internal Medicine, West China Hospital Cancer Center Head And Neck, Sichuan University, Chengdu, China
3 shared publicationsQinjie Wu
A Department of Medical Oncology, Cancer Center, and State Key Laboratory of Biotherapy , West China Hospital, Sichuan University , Chengdu , China
3 shared publications
Latest Publications
- Open Access
- 22 June 2023
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 25 (1) , 37-14
Multiparametric mapping by cardiovascular magnetic resonance imaging in cardiac tumors
- 22 June 2023
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 25 (1) , 37-14
Open AccessMultiparametric mapping by cardiovascular magnetic resonance imaging in cardiac tumors
- Open Access
- 25 July 2022
- Published by Springer Nature in Molecular Cancer
- Vol. 21 (1) , 1-9
CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma
Background: Cell division cycle 6 (CDC6) has been proven to be associated with the initiation and progression of human multiple tumors. However, it’s role in glioma, which is ranked as one of the common primary malignant tumor in the central nervous system and is associated with high morbidity and mortality, is unclear.Methods: In this study, we explored CDC6 gene expression level in pan-cancer. Furthermore, we focused on the relationships between CDC6 expression, its prognostic value, potential biological functions, and immune infiltrates in glioma patients. We also performed vitro experiments to assess the effect of CDC6 expression on proliferative, apoptotic, migrant and invasive abilities of glioma cells.Results: As a result, CDC6 expression was upregulated in multiple types of cancer, including glioma. Moreover, high expression of CDC6 was significantly associated with age, IDH status, 1p/19q codeletion status, WHO grade and histological type in glioma (allp < 0.05). Meanwhile, high CDC6 expression was associated with poor overall survival (OS) in glioma patients, especially in different clinical subgroups. Furthermore, a univariate Cox analysis showed that high CDC6 expression was correlated with poor OS in glioma patients. Functional enrichment analysis indicated that CDC6 was mainly involved in pathways related to DNA transcription and cytokine activity, and Gene Set Enrichment Analysis (GSEA) revealed that MAPK pathway, P53 pathway and NF-κB pathway in cancer were differentially enriched in glioma patients with high CDC6 expression. Single-sample gene set enrichment analysis (ssGSEA) showed CDC6 expression in glioma was positively correlated with Th2 cells, Macrophages and Eosinophils, and negative correlations with plasmacytoid dendritic cells, CD8 T cells and NK CD56bright cells, suggesting its role in regulating tumor immunity. Finally, CCK8 assay, flow cytometry and transwell assays showed that silencing CDC6 could significantly inhibit proliferation, migration, invasion, and promoted apoptosis of U87 cells and U251 cells (p < 0.05).Conclusion: In conclusion, high CDC6 expression may serve as a promising biomarker for prognosis and correlated with immune infiltrates, presenting to be a potential immune therapy target in glioma.
- 25 July 2022
- Published by Springer Nature in Molecular Cancer
- Vol. 21 (1) , 1-9
Open AccessCDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma
Background: Cell division cycle 6 (CDC6) has been proven to be associated with the initiation and progression of human multiple tumors. However, it’s role in glioma, which is ranked as one of the common primary malignant tumor in the central nervous system and is associated with high morbidity and mortality, is unclear.Methods: In this study, we explored CDC6 gene expression level in pan-cancer. Furthermore, we focused on the relationships between CDC6 expression, its prognostic value, potential biological functions, and immune infiltrates in glioma patients. We also performed vitro experiments to assess the effect of CDC6 expression on proliferative, apoptotic, migrant and invasive abilities of glioma cells.Results: As a result, CDC6 expression was upregulated in multiple types of cancer, including glioma. Moreover, high expression of CDC6 was significantly associated with age, IDH status, 1p/19q codeletion status, WHO grade and histological type in glioma (allp < 0.05). Meanwhile, high CDC6 expression was associated with poor overall survival (OS) in glioma patients, especially in different clinical subgroups. Furthermore, a univariate Cox analysis showed that high CDC6 expression was correlated with poor OS in glioma patients. Functional enrichment analysis indicated that CDC6 was mainly involved in pathways related to DNA transcription and cytokine activity, and Gene Set Enrichment Analysis (GSEA) revealed that MAPK pathway, P53 pathway and NF-κB pathway in cancer were differentially enriched in glioma patients with high CDC6 expression. Single-sample gene set enrichment analysis (ssGSEA) showed CDC6 expression in glioma was positively correlated with Th2 cells, Macrophages and Eosinophils, and negative correlations with plasmacytoid dendritic cells, CD8 T cells and NK CD56bright cells, suggesting its role in regulating tumor immunity. Finally, CCK8 assay, flow cytometry and transwell assays showed that silencing CDC6 could significantly inhibit proliferation, migration, invasion, and promoted apoptosis of U87 cells and U251 cells (p < 0.05).Conclusion: In conclusion, high CDC6 expression may serve as a promising biomarker for prognosis and correlated with immune infiltrates, presenting to be a potential immune therapy target in glioma.
- 1 January 2020
- Vol. 24 (14) , 7690-7697
Progress in the study of markers related to glioma prognosis
OBJECTIVE: In the era of precision medicine, molecular and genetic biomarkers act as the key indicators for glioma patients' recurrence and prognosis. MATERIALS AND METHODS: We summarize the biomarkers of glioma prognosis from molecular level, gene level and microRNA level. RESULTS: In molecular biomarkers, cyclinD1 high expression/P16 low expression. MIF high expression and VEGF high expression were all related to glioma patients' poor prognosis; in genetic biomarkers, MGMT promoter methylation absence, IDH1 wild type, HIF-alpha high expression, Chromosome 1p/19q non-deletion and TERT promoter mutation were associated with poor prognosis for glioma; in microRNA biomarkers, miR-524-5p, miR-586, miR-433, miR-619, miR-548d-5p, miR-525-5p, miR-301a, miR-210, miR-10b-5p, miR-15b-5p and miR-NA-182 high expression, miR-124, miR-128, miR-146b and miR-218 low expression were commonly seen in glioma poor prognosis patients. CONCLUSIONS: With the continuous development of science and technology, the diagnosis of glioma will tend to the gene and molecular level. Finding specific markers is helpful for the early diagnosis and accurate prognosis of glioma, which provides the possibility for individualized treatment.
- 1 January 2020
- Vol. 24 (14) , 7690-7697
Progress in the study of markers related to glioma prognosis
OBJECTIVE: In the era of precision medicine, molecular and genetic biomarkers act as the key indicators for glioma patients' recurrence and prognosis. MATERIALS AND METHODS: We summarize the biomarkers of glioma prognosis from molecular level, gene level and microRNA level. RESULTS: In molecular biomarkers, cyclinD1 high expression/P16 low expression. MIF high expression and VEGF high expression were all related to glioma patients' poor prognosis; in genetic biomarkers, MGMT promoter methylation absence, IDH1 wild type, HIF-alpha high expression, Chromosome 1p/19q non-deletion and TERT promoter mutation were associated with poor prognosis for glioma; in microRNA biomarkers, miR-524-5p, miR-586, miR-433, miR-619, miR-548d-5p, miR-525-5p, miR-301a, miR-210, miR-10b-5p, miR-15b-5p and miR-NA-182 high expression, miR-124, miR-128, miR-146b and miR-218 low expression were commonly seen in glioma poor prognosis patients. CONCLUSIONS: With the continuous development of science and technology, the diagnosis of glioma will tend to the gene and molecular level. Finding specific markers is helpful for the early diagnosis and accurate prognosis of glioma, which provides the possibility for individualized treatment.
- Open Access
- 17 October 2019
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 1173
Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
Background: Immune checkpoint blockade has revolutionized the treatment of multiple malignancies. Currently, however, the effect is not universal, with objective response rates (ORR) of about 15–25%, and even lower for some cancers. Abnormal vasculature is a hallmark of most solid tumors and plays a role in immune evasion. Growing body of evidence suggests that vascular normalization and immune reprogramming could operate synergistic effect, resulting in an enhanced therapeutic efficacy. However, the benefit of antitumor efficacy must be weighed against the risk of added toxicity. In this systematic review, we summarize severe toxicity observed in such a kind of combination regimen. Methods: PubMed and Embase were searched for English references published up to May 31, 2019, with MeSH and keywords search terms of immune checkpoint inhibitors (ICIs) and antiangiogenic agents approved for using in solid tumors. Studies performing concomitant use of ICIs and antiangiogenic agents, and also reporting severe treatment-related adverse events (trAEs) (≥grade 3), were included for further analysis. Results: A total of 32 studies including a total of 2,324 participants were analyzed. Limited available data suggests that both antiangiogenic monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) show potential risk of increasing treatment-related toxicity when combined with ICIs. Overall, the total incidence of severe adverse events (AEs) associated with ICIs plus mAbs (44.5%) is lower than that of ICIs plus TKIs (60.1%). However, the trAEs observed in combination therapy are mostly consistent with the known safety profiles of corresponding monotherapy, and they seem to be largely related to antiangiogenic agents, rather than a true immune-related adverse event (irAE) predominantly due to ICIs. The majority of trAEs are intervened by holding ICI treatment and adding corticosteroids, as well as reducing dose or adjusting administration frequency of the antiangiogenic drugs. Conclusions: Concurrent use of ICIs and antiangiogenic agents shows potential treatment-related toxicity. Further research is required to compare the efficacy and safety of the combination regimen and corresponding monotherapy and identify predictive biomarkers, as well as explore dose, duration, and sequencing schedules of drugs.
- 17 October 2019
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 1173
Open AccessAdverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
Background: Immune checkpoint blockade has revolutionized the treatment of multiple malignancies. Currently, however, the effect is not universal, with objective response rates (ORR) of about 15–25%, and even lower for some cancers. Abnormal vasculature is a hallmark of most solid tumors and plays a role in immune evasion. Growing body of evidence suggests that vascular normalization and immune reprogramming could operate synergistic effect, resulting in an enhanced therapeutic efficacy. However, the benefit of antitumor efficacy must be weighed against the risk of added toxicity. In this systematic review, we summarize severe toxicity observed in such a kind of combination regimen. Methods: PubMed and Embase were searched for English references published up to May 31, 2019, with MeSH and keywords search terms of immune checkpoint inhibitors (ICIs) and antiangiogenic agents approved for using in solid tumors. Studies performing concomitant use of ICIs and antiangiogenic agents, and also reporting severe treatment-related adverse events (trAEs) (≥grade 3), were included for further analysis. Results: A total of 32 studies including a total of 2,324 participants were analyzed. Limited available data suggests that both antiangiogenic monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) show potential risk of increasing treatment-related toxicity when combined with ICIs. Overall, the total incidence of severe adverse events (AEs) associated with ICIs plus mAbs (44.5%) is lower than that of ICIs plus TKIs (60.1%). However, the trAEs observed in combination therapy are mostly consistent with the known safety profiles of corresponding monotherapy, and they seem to be largely related to antiangiogenic agents, rather than a true immune-related adverse event (irAE) predominantly due to ICIs. The majority of trAEs are intervened by holding ICI treatment and adding corticosteroids, as well as reducing dose or adjusting administration frequency of the antiangiogenic drugs. Conclusions: Concurrent use of ICIs and antiangiogenic agents shows potential treatment-related toxicity. Further research is required to compare the efficacy and safety of the combination regimen and corresponding monotherapy and identify predictive biomarkers, as well as explore dose, duration, and sequencing schedules of drugs.
- 7 September 2019
- Published by Springer Nature in Molecular Diversity
- Vol. 24 (4) , 1177-1184
One-pot synthesis of substituted pyrrole–imidazole derivatives with anticancer activity
A facile and efficient method to synthesize pyrrole–imidazole was developed via a post-Ugi cascade reaction followed by one purification procedure. Synthesized pyrrole–imidazole was collected by performing a mild reaction and a simple procedure, which could be applicable to a broad scope of functionalized anilines. The screening results demonstrated that compound 7e exhibited a high potency of anticancer activity in human pancreatic cancer cell lines PANC and ASPC-1. Our work shed light on the potential of post-Ugi cascade reaction in combinatorial and medicinal chemistry. Graphic abstract
- 7 September 2019
- Published by Springer Nature in Molecular Diversity
- Vol. 24 (4) , 1177-1184
One-pot synthesis of substituted pyrrole–imidazole derivatives with anticancer activity
A facile and efficient method to synthesize pyrrole–imidazole was developed via a post-Ugi cascade reaction followed by one purification procedure. Synthesized pyrrole–imidazole was collected by performing a mild reaction and a simple procedure, which could be applicable to a broad scope of functionalized anilines. The screening results demonstrated that compound 7e exhibited a high potency of anticancer activity in human pancreatic cancer cell lines PANC and ASPC-1. Our work shed light on the potential of post-Ugi cascade reaction in combinatorial and medicinal chemistry. Graphic abstract
- 1 December 2018
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 7 (6) , 1527-1536
The role of celecoxib for colorectal cancer treatment: a systematic review
Background: Some evidence has suggested that the Cox-2 inhibitor, celecoxib, might improve the survival outcomes in cancer patients. However, the association between celecoxib use and treatment response in colorectal cancer (CRC) patients remains controversial. Thus, a summary on current evidence was performed. Methods: We conducted an electronic search using (PubMed, Web of Science, Embase, and CNKI) to identify relevant peer-reviewed articles, up to March 2018. Eligible study designs included randomized controlled trials (RCTs) and uncontrolled trials (UCTs) with the single experimental arm. The included trials evaluated the effect of adding celecoxib to conventional treatments for patients with CRC on overall response rate (ORR), disease control rate (DCR), pathological response, survival indices, and toxicities. Results: The final analysis included 12 trials with a total of 621 patients. In this study, a qualitative summary and meta-analysis was performed due to insufficient RCTs. The addition of celecoxib showed improvement of pathological response but had no effects on ORR (RR =1.09; 95% CI, 0.62–1.92; P=0.76) and DCR (RR =1.09; 95% CI, 0.94–1.27; P=0.25). The impact of celecoxib on survival indices remains unclear. Meta-analysis on toxicities suggests that celecoxib is well tolerated with a decreased risk of oral mucositis (RR =0.35; 95% CI, 0.18–0.67; P=0.002). Conclusions: Results showed the potential benefits of celecoxib in the treatment of resectable CRC compared with chemotherapy or chemoradiotherapy alone, but there were no effects on ORR/DCR or survival indices. The safety profile was identified in the meta-analysis among CRC patients. The benefit versus harm needs to be carefully considered when celecoxib is recommended in patients with a history of cardiac diseases. In this review, part of the evidence was evaluated from non-RCTs, so further well-designed RCTs in this field are urgently required to confirm our finding.
- 1 December 2018
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 7 (6) , 1527-1536
The role of celecoxib for colorectal cancer treatment: a systematic review
Background: Some evidence has suggested that the Cox-2 inhibitor, celecoxib, might improve the survival outcomes in cancer patients. However, the association between celecoxib use and treatment response in colorectal cancer (CRC) patients remains controversial. Thus, a summary on current evidence was performed. Methods: We conducted an electronic search using (PubMed, Web of Science, Embase, and CNKI) to identify relevant peer-reviewed articles, up to March 2018. Eligible study designs included randomized controlled trials (RCTs) and uncontrolled trials (UCTs) with the single experimental arm. The included trials evaluated the effect of adding celecoxib to conventional treatments for patients with CRC on overall response rate (ORR), disease control rate (DCR), pathological response, survival indices, and toxicities. Results: The final analysis included 12 trials with a total of 621 patients. In this study, a qualitative summary and meta-analysis was performed due to insufficient RCTs. The addition of celecoxib showed improvement of pathological response but had no effects on ORR (RR =1.09; 95% CI, 0.62–1.92; P=0.76) and DCR (RR =1.09; 95% CI, 0.94–1.27; P=0.25). The impact of celecoxib on survival indices remains unclear. Meta-analysis on toxicities suggests that celecoxib is well tolerated with a decreased risk of oral mucositis (RR =0.35; 95% CI, 0.18–0.67; P=0.002). Conclusions: Results showed the potential benefits of celecoxib in the treatment of resectable CRC compared with chemotherapy or chemoradiotherapy alone, but there were no effects on ORR/DCR or survival indices. The safety profile was identified in the meta-analysis among CRC patients. The benefit versus harm needs to be carefully considered when celecoxib is recommended in patients with a history of cardiac diseases. In this review, part of the evidence was evaluated from non-RCTs, so further well-designed RCTs in this field are urgently required to confirm our finding.
- 24 October 2017
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 41 (3) , 496-501
CT-Guided Percutaneous Sclerotherapy for Low-Flow Retrobulbar Intraconal Venous Malformations
Background and Aims Until now, no study has focused exclusively on low-flow retrobulbar intraconal venous malformations (RIVMs) which may require treatment due to cosmetic defect, pain, and visual dysfunction. The treatment for RIVMs which surround the optic nerve remains challenging. This case series aimed to evaluate the technical feasibility, effectiveness, and safety of percutaneous sclerotherapy with polidocanol for low-flow RIVMs, using local anesthesia. Method This is a prospective, non-comparative, single-center, interventional case series. All patients signed informed consent forms. Seven patients with RIVMs were treated with percutaneous sclerotherapy with polidocanol/air foam using CT guidance. Primary endpoints are reduction in the volume of RIVMs and pain relief assessed by visual analog scale (VAS). Secondary endpoints are exophthalmos and recording adverse events obtained in clinical follow-up during outpatient visits. Results Results revealed that the mean volume of RIVMs was decreased from 12.05 ± 6.35 cm3 preoperatively to 1.56 ± 0.43 cm3 postoperatively, (p = 0.005), with a mean decrease of 87.05%. The intraocular pressure was decreased from 14.19 ± 2.99 to 11.79 ± 1.25 mmHg, (p = 0.043). The mean VAS score was decreased from 3.43 ± 2.37 preoperatively to 1.29 ± 0.76 postoperatively, (p = 0.023). The exophthalmos score was decreased from 1.75 ± 0.27 to 1.34 ± 0.31 cm, (p = 0.005). All patients were satisfied with the treatment, which did not leave a postoperative scar. Conclusions The results of percutaneous intralesion injection of polidocanol for RIVMs are encouraging. The present results suggest that this method could be a safe and effective treatment option for patients with RIVMs.
- 24 October 2017
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 41 (3) , 496-501
CT-Guided Percutaneous Sclerotherapy for Low-Flow Retrobulbar Intraconal Venous Malformations
Background and Aims Until now, no study has focused exclusively on low-flow retrobulbar intraconal venous malformations (RIVMs) which may require treatment due to cosmetic defect, pain, and visual dysfunction. The treatment for RIVMs which surround the optic nerve remains challenging. This case series aimed to evaluate the technical feasibility, effectiveness, and safety of percutaneous sclerotherapy with polidocanol for low-flow RIVMs, using local anesthesia. Method This is a prospective, non-comparative, single-center, interventional case series. All patients signed informed consent forms. Seven patients with RIVMs were treated with percutaneous sclerotherapy with polidocanol/air foam using CT guidance. Primary endpoints are reduction in the volume of RIVMs and pain relief assessed by visual analog scale (VAS). Secondary endpoints are exophthalmos and recording adverse events obtained in clinical follow-up during outpatient visits. Results Results revealed that the mean volume of RIVMs was decreased from 12.05 ± 6.35 cm3 preoperatively to 1.56 ± 0.43 cm3 postoperatively, (p = 0.005), with a mean decrease of 87.05%. The intraocular pressure was decreased from 14.19 ± 2.99 to 11.79 ± 1.25 mmHg, (p = 0.043). The mean VAS score was decreased from 3.43 ± 2.37 preoperatively to 1.29 ± 0.76 postoperatively, (p = 0.023). The exophthalmos score was decreased from 1.75 ± 0.27 to 1.34 ± 0.31 cm, (p = 0.005). All patients were satisfied with the treatment, which did not leave a postoperative scar. Conclusions The results of percutaneous intralesion injection of polidocanol for RIVMs are encouraging. The present results suggest that this method could be a safe and effective treatment option for patients with RIVMs.
- Open Access
- 1 September 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (37) , e8018
Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic carcinoma
The aim of this study was to determine the effectiveness of intratumoral injection of chemotherapeutics in improving the quality of life and survival of patients with pancreatic carcinoma. We present a case series of 5 patients with unresectable pancreatic adenocarcinoma. Patients diagnosed with unresectable poorly differentiated pancreatic ductal adenocarcinoma by intraoperative frozen biopsyor percutaneous biopsy. Five patients with unresectable pancreatic adenocarcinoma received a computed tomography-guided percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue. Mean overall survival was 16.2 ± 3.7 months. Local control rates were 100% and 80% at postoperative 3 and 6 months, respectively. Mean Visual Analogue Scale pain score decreased from 7.2 ± .84 preoperatively to 2 ± 1.22 at postoperative 4 weeks. There were no complications associated with the procedure. Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic may be safe and effective.
- 1 September 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (37) , e8018
Open AccessPercutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic carcinoma
The aim of this study was to determine the effectiveness of intratumoral injection of chemotherapeutics in improving the quality of life and survival of patients with pancreatic carcinoma. We present a case series of 5 patients with unresectable pancreatic adenocarcinoma. Patients diagnosed with unresectable poorly differentiated pancreatic ductal adenocarcinoma by intraoperative frozen biopsyor percutaneous biopsy. Five patients with unresectable pancreatic adenocarcinoma received a computed tomography-guided percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue. Mean overall survival was 16.2 ± 3.7 months. Local control rates were 100% and 80% at postoperative 3 and 6 months, respectively. Mean Visual Analogue Scale pain score decreased from 7.2 ± .84 preoperatively to 2 ± 1.22 at postoperative 4 weeks. There were no complications associated with the procedure. Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic may be safe and effective.
- Open Access
- 1 January 2017
- Published by Taylor & Francis in Drug Delivery
- Vol. 24 (1) , 1526-1536
TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors
Active targeting nanoparticles were developed to simultaneously codeliver tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Curcumin (Cur). In the nanoparticles (TRAIL-Cur-NPs), TRAIL was used as both active targeting ligand and therapeutic agent, and Cur could upregulate death receptors (DR4 and DR5) to increase the apoptosis-inducing effects of TRAIL. Compared with corresponding free drugs, TRAIL-Cur-NPs group showed enhanced cellular uptake, cytotoxicity and apoptosis induction effect on HCT116 colon cancer cells. In addition, in vivo anticancer studies suggested that TRAIL-Cur-NPs had superior therapeutic effect on tumors without obvious toxicity, which was mainly due to the high tumor targeting and synergistic effect of TRAIL and Cur. The synergistic mechanism of improved antitumor efficacy was proved to be upregulation of DR4 and DR5 in tumor cells induced by Cur. Thus, the prepared codelivery nanoparticles may have potential applications in colorectal cancer therapy.
- 1 January 2017
- Published by Taylor & Francis in Drug Delivery
- Vol. 24 (1) , 1526-1536
Open AccessTRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors
Active targeting nanoparticles were developed to simultaneously codeliver tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Curcumin (Cur). In the nanoparticles (TRAIL-Cur-NPs), TRAIL was used as both active targeting ligand and therapeutic agent, and Cur could upregulate death receptors (DR4 and DR5) to increase the apoptosis-inducing effects of TRAIL. Compared with corresponding free drugs, TRAIL-Cur-NPs group showed enhanced cellular uptake, cytotoxicity and apoptosis induction effect on HCT116 colon cancer cells. In addition, in vivo anticancer studies suggested that TRAIL-Cur-NPs had superior therapeutic effect on tumors without obvious toxicity, which was mainly due to the high tumor targeting and synergistic effect of TRAIL and Cur. The synergistic mechanism of improved antitumor efficacy was proved to be upregulation of DR4 and DR5 in tumor cells induced by Cur. Thus, the prepared codelivery nanoparticles may have potential applications in colorectal cancer therapy.
- Open Access
- 17 January 2016
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2016 (1) , 3539748
The Protective Effects of Buzui on Acute Alcoholism in Mice
This study was designed to investigate the role of a traditional buzui recipe in anti‐inebriation treatment. Buzui consists of Fructus Schisandrae Chinensis, Fructus Chebulae, Fructus Mume, Fructus Crataegi, Endothelium Corneum Gigeriae Galli, and Excrementum Bombycis. The buzui mixture was delivered by gavage, and ethanol was delivered subsequent to the final treatment. The effects of buzui on the righting reflex, inebriation rates, and the survival curve are depicted. Blood alcohol concentrations, alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels, and alkaline phosphatase (ALP) levels were recorded. The activities of alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), and superoxide dismutase (SOD), as well as malonaldehyde (MDA) levels, were also measured. Our results demonstrated that a traditional buzui recipe showed significant effects on promoting wakefulness and the prevention of acute alcohol intoxication, accelerating the metabolism of alcohol in the liver and reducing the oxidative damage caused by acute alcoholism.
- 17 January 2016
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2016 (1) , 3539748
Open AccessThe Protective Effects of Buzui on Acute Alcoholism in Mice
This study was designed to investigate the role of a traditional buzui recipe in anti‐inebriation treatment. Buzui consists of Fructus Schisandrae Chinensis, Fructus Chebulae, Fructus Mume, Fructus Crataegi, Endothelium Corneum Gigeriae Galli, and Excrementum Bombycis. The buzui mixture was delivered by gavage, and ethanol was delivered subsequent to the final treatment. The effects of buzui on the righting reflex, inebriation rates, and the survival curve are depicted. Blood alcohol concentrations, alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels, and alkaline phosphatase (ALP) levels were recorded. The activities of alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), and superoxide dismutase (SOD), as well as malonaldehyde (MDA) levels, were also measured. Our results demonstrated that a traditional buzui recipe showed significant effects on promoting wakefulness and the prevention of acute alcohol intoxication, accelerating the metabolism of alcohol in the liver and reducing the oxidative damage caused by acute alcoholism.